Clinical Trials :: SCYNEXIS, Inc. (SCYX)

Ongoing Clinical Trials

SCYNERGIA

A Phase 2 Trial - Combination Therapy of Ibrexafungerp (SCY-078) with Voriconazole in Patients with Invasive Pulmonary Aspergillosis

Learn more here

FURI

Open-Label Study to Evaluate the Efficacy and Safety of Ibrexafungerp (SCY-078) in Patients with Refractory or Intolerant Fungal Diseases

Learn more here

CARES

Open-Label Study to Evaluate the Efficacy and Safety of Ibrexafungerp (SCY-078) in Patients with Candidiasis Caused by Candida Auris

Learn more here

CANDLE

Ibrexafungerp for Recurrent Vulvovaginal Candidiasis (RVVC)

SCY-0789-304 is a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC). Enrollment is complete.

ClinicalTrials.gov Identifier: NCT04029116

Learn more here

Interested In Our Clinical Trials?

First Name

Last Name

Institution

Address

Email

Phone

Study Coordinator/Secondary Contact

Email

Phone

Degree

Interested In:

CANDLE

FURI

CARES

SCYNERGIA

Message

I understand that SCYNEXIS may use my information to contact me, and I have read and understand SCYNEXIS’s privacy policy.

If you have any questions, please contact us at ClinicalTrials@SCYNEXIS.com.